Science
Thomson Reuters
Theranos CEO Elizabeth Holmes speaks on stage at the Glamour Women of the Year Awards where she receives an award, in the Manhattan borough of New York
On Wednesday, the blood-testing startup said that Sunny Balwani, the company's president and chief operating officer is stepping down and retiring.
Balwani, who joined Theranos in 2009 also served on the company's board of directors.
Theranos will also be bringing in three new members to its board, including biotech veteran Fabrizio Bonanni. The other two - William Foege and Richard Kovacevich - will move over from Theranos' board of counselors.
Before retiring in 2013, Bonanni had been an executive vice president at Amgen, a biopharmaceutical company in Thousand Oaks, California.
Theranos has been embroiled in a controversy ever since a Wall Street Journal report questioned the accuracy of Theranos' tests. Later, an investigation by the Centers for Medicare and Medicaid Services found that Theranos' northern California lab was putting patients in "immediate jeopardy."
Theranos has since stopped running tests out of that lab and has responded to the agency with plans to address its concerns.
The company said in a release that it also plans to reorganize its structure, "with dedicated corporate divisions for Technology and Clinical Operations."
Balwani's departure is the biggest leadership change to the company since its Northern California lab halted all testing. In April, Theranos also announced the addition of a medical advisory board.